Search Results
Your search for The ,The matches 33932 pages
Showing 2651 - 2700The Role of U.S. Cancer Centers in Preparing Patients With Cancer for Climate Change Emergencies
Investigators have proposed that cancer centers may be uniquely positioned to protect communities and patients with cancer from climate-driven disasters by bolstering climate change–associated emergency preparedness, according to a recent study published by Espinel et al in the Journal of the...
Can an AI Model Improve Mortality Risk Prediction Linked to Lung Cancer or Cardiovascular Disease?
A novel artificial intelligence (AI) model may be able to accurately predict the risk of death from lung cancer, cardiovascular disease, and other causes by using data from low-dose computed tomography (CT) scans of the lungs, according to a recent study published by Xu et al in Radiology....
Selinexor as Maintenance Therapy for p53 Wild-Type Endometrial Cancer
Long-term follow-up of selinexor maintenance therapy in patients with p53 wild-type endometrial cancer has demonstrated anticancer activity, according to data presented by Brian M. Slomovitz, MD, and colleagues during the ASCO Plenary Series: July 2023 Session (Abstract 427956). Results of the...
Primary Cancer and Noncancer Mortality Among Long-Term Survivors of Solid Tumors
In a study reported in JAMA Network Open, KC et al identified factors involved with primary cancer mortality vs noncancer mortality among long-term survivors of breast, prostate, and colorectal cancers. Study Details The study included data on 627,702 patients in the Surveillance, Epidemiology,...
Niraparib Maintenance in Newly Diagnosed Advanced Ovarian Cancer
In a Chinese phase III study reported in JAMA Oncology, Li et al found that niraparib maintenance therapy given with an individualized starting dose improved progression-free survival vs placebo in newly diagnosed patients with advanced ovarian cancer. Study Details In the double-blind multicenter...
Acupuncture May Improve Sleep Among Patients With Multiple Myeloma Undergoing HSCT
An ancient practice may offer modern relief for sleep disturbances experienced by patients with multiple myeloma undergoing hematopoietic stem cell transplant (HSCT), according to research published by El Iskandarani et al in Acupuncture in Medicine. Based on a randomized, prospective study of 63...
Forced Displacement and Diagnosis of Cancer in Syrian Refugees
Syrian migrants, including refugees, may be more likely to be diagnosed with a more advanced stage of breast cancer at a younger age when compared with individuals from Jordan, according to a recent study published by Hazra et al in JAMA Network Open. The new findings suggest the trauma associated...
Vaccine Rollout May Reduce COVID-19–Related Mortality by 84% Among Patients With Cancer, Study Predicts
The rollout of COVID-19 vaccines may be an effective strategy for reducing COVID-19–related hospitalizations and mortality in patients with cancer, according to a recent study published by Starkey et al in Scientific Reports. Study Methods and Results In this study, investigators analyzed the...
Volume of Liver Resected During Gallbladder Surgery May Not Significantly Affect Overall Survival in Patients With Gallbladder Cancer
Investigators have found that overall survival rates may not vary significantly among patients with gallbladder cancer who have had different volumes of their livers resected, as long as the cancer is completely removed, according to a study published by Vega et al in the Annals of Surgical...
Study Explores Incidence and Mortality Rates of Cardiovascular Disease Among Black vs White Cancer Survivors
Black cancer survivors in the United States may experience a higher incidence of cardiovascular disease and associated mortality than White cancer survivors, according to a recent study published by Sung et al in the International Journal of Epidemiology. The investigators also found that...
Polygenic Risk Score and Chemotherapy-Related Subsequent Malignant Neoplasms in Childhood Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Im et al found that a polygenic risk score (PRS) may be useful in stratifying risk for subsequent malignant neoplasms among nonirradiated survivors of childhood cancer according to chemotherapy received. Study Details The study involved...
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases
In a study reported in JAMA Oncology, Katipally et al found that an integrated clinical-molecular classification of colorectal cancer metastases to the liver distinguished risk groups for survival outcomes. Study Details The investigators had previously defined three biologically distinct molecular ...
Atezolizumab, Vemurafenib, and Cobimetinib in Patients With BRAF V600–Mutated Melanoma and CNS Metastases
A revised report of findings from the phase II TRICOTEL study of atezolizumab, vemurafenib, and cobimetinib in patients with melanoma and central nervous system (CNS) metastases was published in The Lancet Oncology by Reinhard Dummer, MD, and colleagues. The first version of trial findings,...
Addition of Nivolumab to SABR in Early-Stage or Isolated Lung Parenchymal Recurrent NSCLC
In the phase II I-SABR trial reported in The Lancet, Chang et al found that the addition of nivolumab to stereotactic ablative radiotherapy (SABR) improved event-free survival in patients with previously untreated stage I or II or isolated parenchymal recurrent node-negative non–small cell lung...
Keeping Staff and Patients Safe From Workplace Violence
The statistics are chilling. According to estimates from the U.S. Bureau of Labor Statistics, workers in the fields of health care and social services are five times more likely to suffer from a workplace violence injury than workers overall.1 The Bureau statistics show that the rate of injuries...
‘I Want to Kill You’
My patient threatened to kill me. I was in the middle of a busy medical oncology clinic. I was seeing her to discuss test results 1 week after I told her I was concerned that her cancer had returned. As I suspected, the test confirmed recurrent cancer, and this time, it was incurable. I walked into ...
ASCO Issues Statements on Recent U.S. Supreme Court Rulings on Affirmative Action, LGBTQ+ Rights
ASCO issued a statement regarding the U.S. Supreme Court decision on affirmative action on June 29. A statement from ASCO Chief Executive Officer, Clifford A. Hudis, MD, FASCO, FACP, follows: “[The] U.S. Supreme Court ruling on affirmative action threatens to reverse hard-won gains in diversity...
ASCO Blueprint Report Captures Steady Progress Toward Equity, Diversity, and Inclusion
The American Society of Clinical Oncology (ASCO) has released its first-ever Equity, Diversity, and Inclusion (EDI) Blueprint Report, highlighting ASCO’s 2022 advancements in the EDI space. The report provides information on 22 initiatives that ASCO launched across the mission pillars of research,...
Implementation of CLINICAL TREATMENT Act Advances, Increasing Access to Cancer Clinical Trials
After direct advocacy from the Association for Clinical Oncology (ASCO) and its members, in December 2019, Congress enacted the CLINICAL TREATMENT Act, which requires all states and territories to cover and reimburse routine costs of care for treating a Medicaid enrollee who is participating in a...
ASCO-CAP Guideline Update Confirms Previous Recommendations for HER2 Testing in Breast Cancer
In partnership with the College of American Pathologists (CAP), ASCO has affirmed findings from its 2018 practice guideline on the use of HER2 testing in breast cancer. Notably, the ASCO/CAP expert panel found there is currently no justification for a new designation of HER2 test results for...
Glofitamab-gxbm for Select Relapsed or Refractory Large B-Cell Lymphomas
On June 15, 2023, the bispecific CD20-directed CD3 T-cell engager glofitamab-gxbm was granted accelerated approval for relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma after at least two lines of...
Congress Sends ASCO-ASTRO–Supported Letter on Cancer Drug Shortages to the HHS and the FDA
As chemotherapy drug shortages continue to delay patient care and alter treatment plans, 70 bipartisan members of Congress sent a letter to the Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) asking for more information on the shortages and for ways...
Expert Point of View: Barbara Pistilli, MD
Barbara Pistilli, MD, Head of the Breast Cancer Unit in the Medical Oncology Department of Gustave Roussy Cancer Center, Villejuif, France, was invited to discuss the TROPiCS-02 updated analysis. She began by pointing out that the target landscape of antibody-drug conjugates is “expanding...
Extended Follow-up of TROPiCS-02 Trial: Sacituzumab Govitecan in Metastatic Breast Cancer
Additional follow-up of the phase III TROPiCS-02 trial has upheld the progression-free and overall survival benefit seen with sacituzumab govitecan-hziy compared with physician’s choice of treatment in patients with endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast...
Investigators Evaluate the Effect of Body Mass Index on Outcomes in Patients With Head and Neck Cancer
Investigators reported that patients with head and neck cancer who had an overweight body mass index (BMI) may have had better outcomes, longer overall and progression-free survival, and lower rates of locoregional failure than those patients with a normal or obese BMI, according to a recent study...
Roundup of Abstracts on New Therapies for Gastrointestinal Cancers From ASCO 2023
The 2023 ASCO Annual Meeting featured thousands of abstracts. In addition to our in-depth coverage of pivotal research from the meeting, The ASCO Post highlights the following studies of novel therapies for gastrointestinal cancers. Addition of Anti-TIGIT Agent in Unresectable Liver Cancer In the...
Expert Point of View: Daniel P. Petrylak, MD
“Clinically, the implications [of the THOR trial] are clear in that all metastatic urothelial cancers should be tested for FGFR mutations,” stated invited discussant Daniel P. Petrylak, MD, of Yale School of Medicine. “This should be done at the beginning of treatment for metastatic disease, as it...
THOR Trial: Erdafitinib Improves Outcomes vs Chemotherapy in FGFR-Altered Advanced Urothelial Carcinoma
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib significantly improved overall survival, progression-free survival, and objective response rates compared with investigator’s choice of chemotherapy in patients with advanced urothelial cancers and FGFR2/3...
Expert Point of View: Corey Speers, MD, PhD, and Julie R. Gralow, MD, FACP, FASCO
ASCO expert Corey Speers, MD, PhD, Professor of Radiation Oncology at the University Hospitals Seidman Cancer Center, Cleveland, provided thoughts on the IELSG37 trial at a press briefing. “The investigators should be congratulated for running the largest ever trial in primary mediastinal B-cell...
Omitting Mediastinal Radiotherapy in Some Patients With Primary Mediastinal B-Cell Lymphoma After Immunochemotherapy
In the largest prospective study of patients with primary mediastinal B-cell lymphoma, radiation therapy was omitted in complete responders to immunochemotherapy without compromising outcomes. These findings were presented at the 2023 ASCO Annual Meeting.1 “Mediastinal radiotherapy may be safely...
Third-Line Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is Part 3 of Clinical Advances in Diffuse Large B-Cell Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Jeremy Abramson, Laurie Sehn, and Kieron Dunleavy discuss the third-line treatment of relapsed/refractory...
Second-Line Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is Part 2 of Clinical Advances in Diffuse Large B-Cell Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Jeremy Abramson, Laurie Sehn, and Kieron Dunleavy discuss the second-line treatment of relapsed/refractory...
Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
This is Part 1 of Clinical Advances in Diffuse Large B-Cell Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Jeremy Abramson, Laurie Sehn, and Kieron Dunleavy discuss the treatment of newly diagnosed high-risk diffuse...
Novel Imaging-Guided Radiotherapy Technique May Reduce Short-Term Side Effects for Patients With Prostate Cancer
The use of magnetic resonance (MR)-guided daily adaptive stereotactic body radiotherapy (SBRT) might make radiation therapy safer for patients with prostate cancer than standard computed tomography (CT)-guided SBRT by helping clinicians more accurately target the prostate while avoiding nearby...
Improving Screening and Surveillance Practices for Early Cancer Detection in Patients With Barrett’s Esophagus
A recent study published in Gastroenterology by Wani et al found that at least a quarter of all esophageal adenocarcinomas may be detected within a year of a negative upper endoscopy in patients with newly diagnosed Barrett's esophagus. The investigators proposed methods for improving the efficacy...
Stereotactic Radiosurgery Before Resection of Brain Metastases From Solid Tumors
In a study reported in JAMA Oncology, Prabhu et al identified outcomes and associated risk factors among patients receiving stereotactic radiosurgery (SRS) prior to resection of brain metastases from solid tumors. Study Details The study involved data from an international multicenter cohort...
Intervention to Increase Uptake of Tobacco Use Treatment for Patients With Cancer Who Smoke
In a study reported in the Journal of Clinical Oncology, Jenssen et al found that electronic health record (EHR)-based nudges to clinicians significantly increased the uptake of tobacco use treatment in patients with cancer who were current smokers. Study Details In the trial—performed across 11...
Olaparib and Temozolomide in Advanced Uterine Leiomyosarcoma
In a phase II trial (NCI Protocol 10250) reported in the Journal of Clinical Oncology, Ingham et al found that the combination of olaparib and temozolomide showed activity in previously treated patients with advanced uterine leiomyosarcoma. Study Details In the multicenter trial, 22 evaluable...
Addition of SBRT to Immunotherapy in Advanced Solid Tumors
In the Belgian phase II CHEERS trial reported in JAMA Oncology, Spaas et al evaluated the addition of stereotactic body radiotherapy (SBRT) to anti–PD-1/PD-L1 immune checkpoint inhibitor therapy, with SBRT directed to a maximum of three lesions, in patients with advanced solid tumors. The...
CLL14: Long-Term Results of Fixed-Duration Venetoclax Plus Obinutuzumab in Elderly Patients With CLL
The 6-year follow-up of a landmark study has revealed significant treatment-free remissions and safety findings in elderly patients with chronic lymphocytic leukemia (CLL) and coexisting medical conditions.1 Long-term results of the CLL14 trial, presented during the European Hematology Association...
Expert Point of View: Ines Vaz-Luis, MD, PhD
The invited discussant of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis, Ines Vaz-Luis, MD, PhD, of the Breast Cancer Survivorship Group, Gustave Roussy, Villejuif, France, pointed out that the benefit of ovarian suppression or ablation in reducing breast cancer...
EBCTCG Meta-analysis Confirms Benefit of Ovarian Ablation or Suppression in Preventing Breast Cancer Recurrence
A meta-analysis of randomized trials has revealed a benefit to ovarian ablation or suppression in preventing breast cancer recurrence in premenopausal women with estrogen receptor–positive tumors.1 The findings, based on almost 15,000 women in studies spanning several decades, were presented at the ...
Overall Survival With Axicabtagene Ciloleucel in Large B-Cell Lymphoma: Results From ZUMA-7
As reported in The New England Journal of Medicine by Jason R. Westin, MD, and colleagues, the overall survival analysis from the phase III ZUMA-7 trial showed significant benefit with axicabtagene ciloleucel vs standard care in patients with early relapsed or refractory large B-cell lymphoma. The...
Individual Patient Meta-analysis of Neoadjuvant Chemotherapy and Chemoradiotherapy for Esophageal or GEJ Carcinoma
In a meta-analysis reported in the Journal of Clinical Oncology, Faron et al found that neoadjuvant chemotherapy and chemoradiotherapy were associated with better survival vs upfront surgery in patients with thoracic esophageal or gastroesophageal junction (GEJ) carcinoma. Study Details The study...
FDA Approves Quizartinib for Newly Diagnosed FLT3-ITD–Positive Acute Myeloid Leukemia
On July 20, the U.S. Food and Drug Administration (FDA) approved quizartinib (Vanflyta) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adults with newly diagnosed acute...
Expert Point of View: Nabil F. Saba, MD, FACP, and Jennifer Choe, MD, PhD
Nabil F. Saba, MD, FACP, Professor and Vice Chair of Hematology and Medical Oncology, the Lynne and Howard Halpern Chair in Head and Neck Cancer Research, and Director of the HNCA Medical Oncology Program at the Winship Cancer Institute, Emory University, Atlanta, was invited to discuss the...
JUPITER-02: Toripalimab Plus Chemotherapy Improved Survival Outcomes for Some Patients With Advanced Nasopharyngeal Carcinoma
In the final overall survival analysis of the phase III JUPITER-02 trial, first-line treatment with toripalimab plus gemcitabine and cisplatin resulted in a statistically significant and clinically meaningful improvement in overall survival and progression-free survival vs chemotherapy alone in...
Psilocybin and Other Psychedelics May Help Patients With Late-Stage Gynecologic Cancer Tackle Mental Health Symptoms
Investigators revealed that psilocybin-assisted psychotherapy and other psychedelics may effectively ease symptoms of anxiety and depression in patients with late-stage gynecologic cancers, according to a new commentary published by Yaniv et al in the International Journal of Gynecological Cancer. ...
Biological Aging and Radiation Therapy for Breast Cancer
Some patients who have received treatment for breast cancer may experience increased biological aging compared with those who have never been diagnosed with breast cancer, according to a new study published by Kresovich et al in the Journal of the National Cancer Institute. The findings showed that ...
First-Line Atezolizumab vs Single-Agent Chemotherapy in Patients With Advanced NSCLC Ineligible for Platinum-Based Chemotherapy
In the phase III IPSOS trial reported in The Lancet, Lee et al found that first-line atezolizumab improved overall survival vs single-agent chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) who were ineligible for platinum-based chemotherapy. Study Details In the open-label...
